Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation.

MLA

Sullivan, Erin M., et al. “Pathologic Risk-Based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation.” Journal of Pediatric Hematology/Oncology, vol. 36, no. 6, Aug. 2014, pp. e335–40. EBSCOhost, https://doi.org/10.1097/MPH.0000000000000141.

APA

Sullivan, E. M., Wilson, M. W., Billups, C. A., Wu, J., Merchant, T. E., Brennan, R. C., Haik, B. G., Shulkin, B., Free, T. M., Given, V., Rodriguez-Galindo, C., & Qaddoumi, I. (2014). Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. Journal of Pediatric Hematology/Oncology, 36(6), e335–e340. https://doi.org/10.1097/MPH.0000000000000141

Chicago

Sullivan, Erin M, Matthew W Wilson, Catherine A Billups, Jianrong Wu, Thomas E Merchant, Rachel C Brennan, Barrett G Haik, et al. 2014. “Pathologic Risk-Based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation.” Journal of Pediatric Hematology/Oncology 36 (6): e335–40. doi:10.1097/MPH.0000000000000141.